Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

计划入组 130 人 · 首次发布于 2017 年 7 月 2 日

Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications

计划入组 110 人 · 首次发布于 2023 年 11 月 7 日

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

计划入组 94 人 · 首次发布于 2023 年 2 月 13 日

Lutetium Lu 177 dotatate(Lutathera)

C₆₅H₈₇LuN₁₄O₁₉S₂

Lutetium-177 oxodotreotide (Curium Pharma)

Lutetium Lu-177(Lutathera, Lumark, EndolucinBeta, Lutetium (177Lu) chloride Billev (previously Illuzyce))

Lu

Laureate Institute for Brain Research

United States

Aveta Biomics, Inc.

United States

Selcuk University

Turkey

Lutetium Lu 177 Dotatate Shows Promise in Metastatic Bronchopulmonary Neuroendocrine Tumors

Lutetium Lu 177 Dotatate Demonstrates Significant Efficacy in Advanced Intracranial Meningioma Phase 2 Trial

Nanopharmaceutics Completes Enrollment in Phase 2 Neuroendocrine Tumor Study Combining Triapine with Lutetium Lu 177 Dotatate